念珠菌显色琼脂 英文名称: Chromogenic Candida Agar | ||||||||||||||||||||||||||||||||||||||||||||||
型号:null 产品货号: CM1002 | ||||||||||||||||||||||||||||||||||||||||||||||
价格:请致电:010-57128832,18610462672 | ||||||||||||||||||||||||||||||||||||||||||||||
品牌: 英国 | ||||||||||||||||||||||||||||||||||||||||||||||
BRILLIANCE CANDIDA AGAR CODE: CM1002 Brilliance™ Candida Agar (formerly Oxoid Chromogenic Candida Agar (OCCA)) is a selective diffrential medium for the rapid isolation and identification of clinically important Candida species.
* Adjusted as required to meet performance standardsBRILLIANCE CANDIDA SELECTIVE SUPPLEMENT Code: SR0231
Directions Description Serious infections due to Candida species are becoming increasingly prevalent. This poses particular problems because of the increasing incidence of non-albicans spp. and the emergence of non-albicans isolates resistant to both amphotericin B and the newer azoles1. Candida species are the fourth most commonly encountered nosocomial pathogens in bloodstream infections in the United States, and candidiasis is associated with mortality rates as high as 60% in immuno-suppressed patients. Of the Candida spp. encountered in clinical practice, Candida albicans is the most common, and this species is usually susceptible to the azole group of antifungal agents. However, it is the shift toward the isolation of more azole-tolerant species, such as Candida glabrata, Candida tropicalis, and Candida krusei, due to the increasing use of itraconazole and fluconazole as the antifungal drugs of first choice for candidiasis, which is causing greatest concern. Rapid identification of the Candida spp. causing infection is, therefore, critical for the clinician in determining the correct antifungal therapy2. For Candida species involved in bloodstream infections on ICUs, it was shown by Ibrahim et al.3 that initial therapy was inadequate in 95% of the cases because no antifungal agent was administered. Due to this inadequacy in the initial treatment, a mortality rate of about 60% was observed in the patient group with Candida infections. Hence, early recognition of a Candida infection would help a clinician to select proper treatment. Combined with rapid identification of the causative organism, this treatment could be optimized to include a non-azole group anti-fungal agent, if required, at an early stage of the infection. Brilliance Candida Agar incorporates two chromogens that indicate the presence of the target enzymes:
The typical enzyme patterns of Candida spp. are shown in Table 1. An opaque agent has been incorporated into the formulation to improve the colour definition on the agar. The broad-spectrum antibacterial agent, chloramphenicol, is added to the agar at 500mg/l to inhibit bacterial growth on the plates. Technique Table 1: Table of expected reactions on Brilliance Candida Agar
Notes: † Candida glabrata, Candida kefyr, Candida parapsilosis and Candida lusitaniae appear as a variety of beige/brown/yellow colours, due to the mixture of natural pigmentation and some alkaline phosphatase activity. Experienced users may be able to differentiate these species by colour and colony morphology. For further instructions on the use and interpretation of Brilliance Candida Agar, simply download the data sheet (643KB) in PDF format. Please confirm prepared media codes with your local supplier. Storage conditions and Shelf Life Appearance Quality control
|